The earnings call for Amgen Inc. revealed strong quarterly results with total revenues growing 5% and adjusted earnings per share increasing 3%. The company highlighted the growth of its two largest products, Enbrel and Neulasta, as well as the continued success of Prolia and XGEVA globally. Key updates included positive Phase 3 data for T-Vec and trebananib, and the expected pivotal data for PCSK9 in the first quarter of 2014. Additionally, Amgen announced collaborations with Astellas and Zhejiang Beta Pharma, which will allow it to bring its medicines directly to patients in Japan and China. The company also discussed its M&A strategy, focusing on assets that offer attractive growth prospects and return on capital. While the stock market remains challenging, Amgen's strong financial performance and strategic initiatives suggest long-term potential.

**Rating:** 1